Литература. 
Риск развития желудочно-кишечных побочных эффектов у пациентов, принимающих ингибиторы циклооксигеназы-2, в сравнении с неселективными нестероидными противовоспалительными препаратами

1. The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (cox-II inhibitors) for rheumatoid arthritis and osteoarthritis / National Institute for Clinical Excellence. — London: NICE, 2000.

2. Hooper L., Brown T., Elliott R., Payne K., Roberts C., Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review // BMJ 2004; 329: 948−52.

3. Juni P., Rutjes A.W.S., Dieppe P. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? // BMJ 2002; 324: 1287−8.

4. Wright J.M. The double-edged sword of COX-2 selective NSAIDs // CMAJ 2002; 167: 1131−7.

5. Jones R. Efficacy and safety of Cox 2 inhibitors // BMJ 2002; 325: 607−8.

6. Micklewright R., Lane S., Linley C., Thompson F., Maskrey N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors // Ailment. Pharmacol. Ther. 2003; 17: 321−32.

7. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2-specific inhibitor, ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized double-blind placebo controlled trial // Arthritis. Rheum. 2000; 43: 370−7.

8. Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis // BMJ 2005; 330: 1366−9.

9. Morris R., Carstairs V. Which deprivation? A comparison of selected deprivation indexes // J. Public Health Med 1991; 13: 318−26.

10. Eachus J., Williams M., Chan P., Davey Smith G., Grainge M., Donovan J., et al. Deprivation and cause specific mortality: evidence from the Somerset and Avon survey of health // BMJ 312; 312: 287−92.

11. Hippisley-Cox J., Groom L., Kendrick D., Coupland C., Webber E., Savelyich B. Cross sectional survey of socioeconomic variations in severity and mechanism of childhood injuries in Trent 1992;7 // BMJ 2002; 324: 1132.

12. Payne N., Saul C. Variations in the use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality // BMJ 1997; 314: 257−61.

13. Pollock A., Vickers N. Deprivation and emergency admissions for cancers of the colorectum, lung, and breast in South East England: ecolological study // BMJ 1998; 317: 245−52.

14. Roper N., Bilous R., Kelly W., Unwin N., Connolly V. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study // BMJ 2001: 1389−93.

15. Key health statistics from general practice / Office of National Statistics. — London: Department of Health, 1998.

16. Hippisley-Cox J., Pringle M. Prevalence, care and outcomes for patients with diet controlled diabetes in general practice: cross sectional survey // Lancet 2004; 364: 423−5.

17. Hammersley V., Hippisley-Cox J., Wilson A., Pringle M. A comparison of research general practices and their patients with other practices — cross sectional survey in Trent // Brit. J. Gen. Pract. 2002; 52: 463−8.

18. Hippisley-Cox J., Hammersley V., Pringle M., Coupland C., Crown N., Wright L. How useful are general practice databases for research? Analysis of their accuracy and completeness in one research network // Health Inform J. 2004; 10: 91−109.

19. Hippisley-Cox J., Pringle M., Hammersley V., Crown N., Meal A., Wynn A. Antidepressants as a risk factor for ischaemic heart disease: case-control study in general practice // BMJ 2001; 323: 666−9.

20. Schlienger R., Jick H., Meier C.R. Use of non steroidal anti-inflammatory drugs and risk of first time acute myocardial infarction // Br. J. Clin. Pharmacol. 2002; 54: 327−32.

21. Jick H., Vasilakis C., Derby L.E. Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension // Epidemiology 1997; 8: 446−8.

22. Meier C.R., Jick S.S., Derby L.E., Vasilakis C., Jick H. Acute respiratory infections and risk of first time acute myocardial infarction // Lancet 1998; 351: 1467−71.

23. Hippisley-Cox J., Pringle M. Depression and risk of ischaemic heart disease in men: authors' reply // BMJ 1998; 316.

24. MacDonald T.M., Morant S.V., Goldstein J.L., Burke T.A., Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs // Gut 2003; 52: 1265−70.

25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) / Scandinavian Simvastatin Survival Group // Lancet 1994; 344: 1383−9.

26. Henry D., Lim J., Garcia Rodriguez L., Perez Gutthann S., Carson J.L., Griffin M., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis // BMJ 1996; 312: 1563−6.

27. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia // Lancet 2000; 356: 1627−31.

28. Jick H., Kaye J., Vasilakis-Scaramozza C., Jick S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis // BMJ 2000; 321: 1190−5.

29. Hippisley-Cox J., Pringle M., Cater R., Wynn A., Hammersely V., Coupland C., et al. The electronic record in primary care — regression or progression? A cross sectional study // BMJ 2003; 326: 1439−43.

30. Rothman K., Greenland S. Modern epidemiology. — 2nd ed. — Boston: Lippincott-Raven, 1998. — Vol. 1.

31. Blatchford O., Davidson L.A., Murray W.R., Blatchford M., Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study // BMJ 1997; 315: 510−4. побочный риск циклооксигеназа нестероидный.

32. Rockall T., Lofan R., Devlin H., Northfield T. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom // BMJ 1995; 311: 222−6.